Stockreport

Kitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy Conference

KITOV PHARAMCEUTICALS HOLDINGS LTD AMERICAN DEPOS  (KTOV) 
US:NASDAQ Investor Relations: kitovpharma.com
PDF Treatment with NT219 in combination with Keytruda® or Erbitux® converted non-responding tumors to responders TEL AVIV, Israel, Sept. 26, 2018 (GLOBE NEWSWIRE) - [Read more]